David Roman
Stock Analyst at Goldman Sachs
(1.96)
# 2,998
Out of 4,876 analysts
43
Total ratings
39.13%
Success rate
-4.08%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HQY HealthEquity | Maintains: Neutral | $94 → $104 | $104.86 | -0.82% | 3 | Jun 4, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $16 | $14.99 | +6.74% | 1 | May 30, 2025 | |
| PODD Insulet | Initiates: Buy | $380 | $309.83 | +22.65% | 1 | May 30, 2025 | |
| DOCS Doximity | Maintains: Neutral | $80 → $50 | $60.41 | -17.23% | 3 | May 21, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Neutral | $120 → $104 | $91.74 | +13.36% | 2 | May 6, 2025 | |
| TDOC Teladoc Health | Maintains: Buy | $13 → $10 | $8.05 | +24.22% | 4 | May 1, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Buy | $94 → $82 | $74.86 | +9.54% | 3 | May 1, 2025 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $24 → $23 | $17.90 | +28.49% | 2 | Apr 16, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $138 → $154 | $133.67 | +15.21% | 2 | Mar 4, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $42 → $24 | $19.11 | +25.59% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $63 → $71 | $74.63 | -4.86% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $55 | $45.83 | +20.02% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $42 | $30.50 | +37.70% | 3 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $91 → $124 | $152.69 | -18.79% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $384 → $427 | $390.40 | +9.38% | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $90 | $77.15 | +16.66% | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $90 | $104.58 | -13.94% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $500 | $534.19 | -6.40% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $274 | $169.97 | +61.20% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $83 | $86.18 | -3.69% | 1 | May 30, 2024 |
HealthEquity
Jun 4, 2025
Maintains: Neutral
Price Target: $94 → $104
Current: $104.86
Upside: -0.82%
Beta Bionics
May 30, 2025
Initiates: Neutral
Price Target: $16
Current: $14.99
Upside: +6.74%
Insulet
May 30, 2025
Initiates: Buy
Price Target: $380
Current: $309.83
Upside: +22.65%
Doximity
May 21, 2025
Maintains: Neutral
Price Target: $80 → $50
Current: $60.41
Upside: -17.23%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $91.74
Upside: +13.36%
Teladoc Health
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $8.05
Upside: +24.22%
GE HealthCare Technologies
May 1, 2025
Maintains: Buy
Price Target: $94 → $82
Current: $74.86
Upside: +9.54%
Kestra Medical Technologies
Apr 16, 2025
Maintains: Neutral
Price Target: $24 → $23
Current: $17.90
Upside: +28.49%
Abbott Laboratories
Mar 4, 2025
Maintains: Buy
Price Target: $138 → $154
Current: $133.67
Upside: +15.21%
Tandem Diabetes Care
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $24
Current: $19.11
Upside: +25.59%
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $74.63
Upside: -4.86%
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $45.83
Upside: +20.02%
Feb 26, 2025
Reinstates: Buy
Price Target: $42
Current: $30.50
Upside: +37.70%
Feb 24, 2025
Maintains: Neutral
Price Target: $91 → $124
Current: $152.69
Upside: -18.79%
Jan 30, 2025
Maintains: Neutral
Price Target: $384 → $427
Current: $390.40
Upside: +9.38%
Dec 5, 2024
Maintains: Buy
Price Target: $81 → $90
Current: $77.15
Upside: +16.66%
May 30, 2024
Initiates: Buy
Price Target: $90
Current: $104.58
Upside: -13.94%
May 30, 2024
Initiates: Buy
Price Target: $500
Current: $534.19
Upside: -6.40%
May 30, 2024
Initiates: Buy
Price Target: $274
Current: $169.97
Upside: +61.20%
May 30, 2024
Initiates: Sell
Price Target: $83
Current: $86.18
Upside: -3.69%